{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T01:20:11Z","timestamp":1789003211929,"version":"build-2803163510"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T00:00:00Z","timestamp":1713398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T00:00:00Z","timestamp":1713398400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cardiothorac Surg"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Patients requiring coronary artery bypass grafting (CABG) are often loaded with antithrombotic drugs (AT) and are at an increased risk for perioperative bleeding complications. Active AT removal by a hemoadsorption cartridge integrated in the cardiopulmonary bypass circuit is increasingly used in this setting to reduce bleeding, and herein we describe the extension of this application in patients on AT undergoing off-pump coronary artery bypass (OPCAB).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Ten patients (80% male; mean age: 67.4\u2009\u00b1\u20099.2years) were treated with ticagrelor (eight patients), rivaroxaban and ticagrelor (one patient), and rivaroxaban (one patient) prior to OPCAB surgery. AT\u2019s were discontinued one day before surgery in nine patients and on the day of surgery in one patient, and all patients were also on aspirin. The cohort mean EuroSCORE-II was 2.9\u2009\u00b1\u20091.5%. A hemoadsorption cartridge was integrated into a dialysis device\u00a0(n=4) or a stand-alone apheresis pump (n=6)\u00a0periprocedural, for a treatment time of\u00a0145\u00a0\u00b1\u00a033 min. Outcome measures included bleeding according to Bleeding Academic Research Consortium (BARC)-4 and 24-hour chest-tube-drainage (CTD).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Mean operation time was 184\u2009\u00b1\u200935\u00a0min. All patients received a left internal thoracic artery with a mean of 2.3\u2009\u00b1\u20090.9 total grafts. One patient had a BARC-4 bleeding event and there were no surgical re-explorations for bleeding. Mean 24-hours CTD was 680\u2009\u00b1\u2009307mL. During follow-up of 19.5\u2009\u00b1\u200917.0 months, none of the patients died or required further reinterventions. No device-related adverse events were reported.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Hemoadsorption via a stand-alone apheresis pump during OPCAB surgery was feasible and safe. This innovative and new approach showed favorable bleeding rates in patients on antithrombotic drugs requiring bypass surgery.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13019-024-02772-1","type":"journal-article","created":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T03:44:13Z","timestamp":1713411853000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Antithrombotic drug removal with hemoadsorption during off-pump coronary artery bypass grafting"],"prefix":"10.1186","volume":"19","author":[{"given":"Helmut","family":"Mair","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Ulrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dow","family":"Rosenzweig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Goeppl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Jurma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferdinand","family":"Vogt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedikt","family":"Baumer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Vogel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Lamm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,18]]},"reference":[{"issue":"3","key":"2772_CR1","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1093\/eurheartj\/ehx419","volume":"39","author":"M Valgimigli","year":"2018","unstructured":"Valgimigli M, Bueno H, Byrne RA, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-thoracic surgery (EACTS). Eur Heart J. 2018;39(3):213\u201360.","journal-title":"Eur Heart J"},{"issue":"2","key":"2772_CR2","doi-asserted-by":"publisher","first-page":"e000651","DOI":"10.1136\/openhrt-2017-000651","volume":"4","author":"S Degrauwe","year":"2017","unstructured":"Degrauwe S, Pilgrim T, Aminian A, et al. Dual antiplatelet therapy for secondary prevention of coronary artery disease. Open Heart. 2017;4(2):e000651.","journal-title":"Open Heart"},{"issue":"4","key":"2772_CR3","doi-asserted-by":"publisher","first-page":"e008226","DOI":"10.1161\/CIRCINTERVENTIONS.119.008226","volume":"13","author":"S Sorrentino","year":"2020","unstructured":"Sorrentino S, Sartori S, Baber U, et al. Bleeding risk, Dual Antiplatelet Therapy Cessation, and adverse events after percutaneous coronary intervention: the PARIS Registry. Circ Cardiovasc Interv. 2020;13(4):e008226.","journal-title":"Circ Cardiovasc Interv"},{"issue":"2","key":"2772_CR4","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1093\/eurheartj\/ehv381","volume":"37","author":"EC Hansson","year":"2016","unstructured":"Hansson EC, Jideus L, Aberg B, et al. Coronary artery bypass grafting-related bleeding complications in patients treated with ticagrelor or clopidogrel: a nationwide study. Eur Heart J. 2016;37(2):189\u201397.","journal-title":"Eur Heart J"},{"issue":"1","key":"2772_CR5","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.athoracsur.2018.12.032","volume":"108","author":"K Hassan","year":"2019","unstructured":"Hassan K, Kannmacher J, Wohlmuth P, et al. Cytosorb Adsorption during Emergency Cardiac operations in patients at high risk of bleeding. Ann Thorac Surg. 2019;108(1):45\u201351.","journal-title":"Ann Thorac Surg"},{"issue":"3","key":"2772_CR6","doi-asserted-by":"publisher","first-page":"186","DOI":"10.5761\/atcs.oa.21-00154","volume":"28","author":"K Hassan","year":"2022","unstructured":"Hassan K, Bruning T, Caspary M, et al. Hemoadsorption of Rivaroxaban and Ticagrelor during Acute Type A Aortic Dissection operations. Ann Thorac Cardiovasc Surg. 2022;28(3):186\u201392.","journal-title":"Ann Thorac Cardiovasc Surg"},{"key":"2772_CR7","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.xjon.2023.04.013","volume":"15","author":"K Hassan","year":"2023","unstructured":"Hassan K, Geidel S, Zamvar V, et al. Intraoperative ticagrelor removal via hemoadsorption during on-pump coronary artery bypass grafting. JTCVS Open. 2023;15:190\u20136.","journal-title":"JTCVS Open"},{"issue":"1","key":"2772_CR8","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s13613-022-01017-5","volume":"12","author":"C Scharf","year":"2022","unstructured":"Scharf C, Weinelt F, Schroeder I, et al. Does the cytokine adsorber CytoSorb((R)) reduce Vancomycin exposure in critically ill patients with sepsis or septic shock? A prospective observational study. Ann Intensive Care. 2022;12(1):44.","journal-title":"Ann Intensive Care"},{"issue":"5","key":"2772_CR9","doi-asserted-by":"publisher","first-page":"e0688","DOI":"10.1097\/CCE.0000000000000688","volume":"4","author":"J Scheier","year":"2022","unstructured":"Scheier J, Nelson PJ, Schneider A, et al. Mechanistic considerations and pharmacokinetic implications on Concomitant Drug Administration during CytoSorb Therapy. Crit Care Explor. 2022;4(5):e0688.","journal-title":"Crit Care Explor"},{"issue":"2","key":"2772_CR10","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.jacbts.2017.01.007","volume":"2","author":"GO Angheloiu","year":"2017","unstructured":"Angheloiu GO, Gugiu GB, Ruse C, et al. Ticagrelor removal from human blood. JACC Basic Transl Sci. 2017;2(2):135\u201345.","journal-title":"JACC Basic Transl Sci"},{"issue":"1\u20133","key":"2772_CR11","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1159\/000484923","volume":"45","author":"A Koertge","year":"2018","unstructured":"Koertge A, Wasserkort R, Wild T, et al. Extracorporeal hemoperfusion as a potential therapeutic option for critical Accumulation of Rivaroxaban. Blood Purif. 2018;45(1\u20133):126\u20138.","journal-title":"Blood Purif"},{"issue":"5","key":"2772_CR12","doi-asserted-by":"publisher","first-page":"e369","DOI":"10.1016\/j.athoracsur.2020.03.108","volume":"110","author":"H Mair","year":"2020","unstructured":"Mair H, Jilek C, Haas B, et al. Ticagrelor and Rivaroxaban Elimination with CytoSorb Adsorber before Urgent off-pump coronary bypass. Ann Thorac Surg. 2020;110(5):e369\u201370.","journal-title":"Ann Thorac Surg"},{"issue":"23","key":"2772_CR13","doi-asserted-by":"publisher","first-page":"2736","DOI":"10.1161\/CIRCULATIONAHA.110.009449","volume":"123","author":"R Mehran","year":"2011","unstructured":"Mehran R, Rao SV, Bhatt DL, et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation. 2011;123(23):2736\u201347.","journal-title":"Circulation"},{"issue":"8","key":"2772_CR14","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1093\/ehjcvp\/pvac036","volume":"8","author":"R Tripathi","year":"2022","unstructured":"Tripathi R, Morales J, Lee V, et al. Antithrombotic drug removal from whole blood using haemoadsorption with a porous polymer bead sorbent. Eur Heart J Cardiovasc Pharmacother. 2022;8(8):847\u201356.","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"1","key":"2772_CR15","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1186\/s13256-023-03949-3","volume":"17","author":"V Dalmastri","year":"2023","unstructured":"Dalmastri V, Angelini A, Minerva V, et al. Extracorporeal hemoadsorption therapy as a potential therapeutic option for rapid removal of Apixaban in high risk-surgical patients: a case report. J Med Case Rep. 2023;17(1):283.","journal-title":"J Med Case Rep"},{"issue":"7","key":"2772_CR16","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1080\/13645706.2022.2104617","volume":"31","author":"A Nierhaus","year":"2022","unstructured":"Nierhaus A, Morales J, Wendt D, et al. Comparison of the CytoSorb((R)) 300 mL and Jafron HA380 hemoadsorption devices: an in vitro study. Minim Invasive Ther Allied Technol. 2022;31(7):1058\u201365.","journal-title":"Minim Invasive Ther Allied Technol"},{"issue":"4","key":"2772_CR17","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1097\/EJA.0000000000001803","volume":"40","author":"S Kietaibl","year":"2023","unstructured":"Kietaibl S, Ahmed A, Afshari A, et al. Management of severe peri-operative bleeding: guidelines from the European Society of Anaesthesiology and Intensive Care: second update 2022. Eur J Anaesthesiol. 2023;40(4):226\u2013304.","journal-title":"Eur J Anaesthesiol"}],"container-title":["Journal of Cardiothoracic Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13019-024-02772-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13019-024-02772-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13019-024-02772-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T03:44:46Z","timestamp":1713411886000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiothoracicsurgery.biomedcentral.com\/articles\/10.1186\/s13019-024-02772-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,18]]},"references-count":17,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["2772"],"URL":"https:\/\/doi.org\/10.1186\/s13019-024-02772-1","relation":{},"ISSN":["1749-8090"],"issn-type":[{"value":"1749-8090","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,18]]},"assertion":[{"value":"27 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Helmut Mair received speaker honoraria and travel fees from CytoSorbents Europe, Berlin, Germany. All other authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"246"}}